PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE Russian patent published in 2017 - IPC C07D487/04 C07D471/04 C07D495/04 C07D519/00 C07D498/04 A61K31/4985 A61K31/501 A61K31/5025 A61K31/506 A61K31/5383 A61K31/551 A61P35/00 A61P9/00 A61P25/00 A61P29/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound selected from formula I, or its stereoisomers, or pharmaceutically acceptable salts thereof, where R¹ is optionally substituted C₁-C₃ alkyl; R², R³ and R⁴ are independently selected from H, F, Cl; R⁵ is selected from (i) optionally substituted C₆-C₂₀ aryl, selected from phenyl; (ii) optionally substituted C₅-C₂₀ heteroaryl, selected from pyrazolyl, pyridinyl, pyrimidinyl, tetrahydroisoquinolinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, 4,6,7-trihydropyrazolo[3,2-c][1,4]oxazinyl, 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 2,3-dihydro-1H-isoindolyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl; (iii) optionally substituted -(C₆-C₂₀ aryl)-(C₃-C₂₀ heterocyclyl), where heterocyclyl is selected from azetidinyl, piperidinyl, morpholino, piperazinyl; (iv) optionally substituted -(C₅-C₂₀ heteroaryl)-(C₃-C₂₀ heterocyclyl), where heteroaryl is selected from pyridinyl and pyridazinyl and heterocyclyl is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 2,6-diazaspiro[3.3]heptanyl, 7,9-diazabicyclo[3.3.1]nonanyl, hexahydropyrrolo[3,4-c]pyrrolyl, morpholino; (v) optionally substituted -(C₅-C₂₀ heteroaryl)-(C₁-C₆ alkyl), where heteroaryl is selected from pirazolyl and pyridinyl; or (vi) optionally substituted -(C₅-C₂₀ heteroaryl)-C(=O)-(C₃-C₂₀ heterocyclyl), selected from (pyridinyl)-C(=O)-(morpholino); R⁶ represents H or C₁-C₃ alkyl; Y¹ and Y² are independently selected from CR⁶ and N; where C₁-C₃ alkyl, C₃-C₂₀ heterocyclyl, C₆-C₂₀ aryl and C₅-C₂₀ heteroaryl optionally substituted with one to three groups, independently selected from D, F, Cl, Br, I, -CH₃, -CH₂CH₃, -CH₂CH(CH₃)₂, -CH₂OH, -CH₂CH₂OH, -C(CH₃)₂OH, -CH₂F, -OC(O)CH₃, -COCH₃, -NHCH₃, -N(CH₃)₂, =O, -OH, -OCH₃, -OCH₂CH₂N(CH₃)₂, -OP(O)(OH)₂, -CH₂OCH₃, cyclopropyl, azetidinyl, 1-(methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, oxetanyl and morpholino; where group (a), formed Z¹, Z², Z³, Z⁴, Z⁵, X and NC(O), forms structure, given in claim, and wherein wavy line indicates bonding point. Invention relates to a pharmaceutical composition for treating a condition, mediated by Bruton's tyrosine kinase, containing a compound of formula (I) and a pharmaceutically acceptable carrier, lubricant, a diluent or filler. Compounds of formula (I) are intended for use as a drug for treating cancer, mediated by Bruton's tyrosine kinase.

EFFECT: pyridone and aza-pyridone compounds for treating disorders mediated by Bruton's tyrosine kinase (Btk).

20 cl, 9 dwg, 4 tbl, 907 ex

(а)